<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978965</url>
  </required_header>
  <id_info>
    <org_study_id>MPASNPVienna</org_study_id>
    <nct_id>NCT00978965</nct_id>
  </id_info>
  <brief_title>Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs</brief_title>
  <official_title>Identification of Patients With High Probability of Not or Poorly Responding to Mycophenolate-mofetil (Cellcept®) or Mycophenolate-natrium (Myfortic®) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to define groups of patients (among patients with a heart or kidney&#xD;
      graft or a glomerular disease and nephrotic range proteinuria) who would either not profit&#xD;
      from a therapy with mycophenolate-mofetil (MMF) or need a higher than conventional dose to&#xD;
      respond.&#xD;
&#xD;
      Mainly there are 2 possible explanations for inter-patient differences in responsiveness to&#xD;
      MMF therapy:&#xD;
&#xD;
        1. Based on a mutation (in this study single nucleotide polymorphisms-SNPs-) in the inosine&#xD;
           monophosphate dehydrogenase 2 (IMPDH 2) transcript as the target enzyme of mycophenolic&#xD;
           acid (MPA) pathway, MMF cannot exert its effect.&#xD;
&#xD;
        2. Based on a high enzyme activity of IMPDH 2 a higher MMF dose than in the conventional&#xD;
           regimens is needed.&#xD;
&#xD;
      To study the significance of these possible explanations there are 4 objectives in this&#xD;
      study:&#xD;
&#xD;
      Objective 1: Since there are no data on SNPs with functional relevance in IMPDH 2 transcript,&#xD;
      we will first sequence all 14 exons of this gene in their entirety in 100 gender and age&#xD;
      matched healthy individuals.&#xD;
&#xD;
      Objective 2: The functional relevance of a detected SNP will be tested in vitro in a&#xD;
      lymphocyte proliferation assay using various MPA concentrations.&#xD;
&#xD;
      Objective 3: These functionally relevant SNPs will be searched in patients with kidney graft&#xD;
      in a retrospective as well as prospective manner.&#xD;
&#xD;
      Objective 4: Parallel to the genotyping experiments, IMPDH 2 activity and MPA plasma levels&#xD;
      will be measured in all patients recruited in the study prospectively.&#xD;
&#xD;
      An association between these SNPs or various IMPDH 2 activity / MPA plasma levels with MMF&#xD;
      responsiveness will be examined.&#xD;
&#xD;
      Objective 5: Strongyloides IgG titers are screened to evaluate the prevalence of helminth&#xD;
      carriers in patients with immunosuppressive therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 9, 2020</completion_date>
  <primary_completion_date type="Actual">September 9, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of functionally relevant SNPs in IMPDH 2 gene.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The association of detected SNPs in inosine monophosphate dehydrogenase-2 transcript or high IMPDH 2 activity with the lack of response to MPA therapy defined as - number of biopsy proven acute rejections in the first year after transplantation</measure>
    <time_frame>12 months per patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Screening for strongyloides IgG titers</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">277</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>MPA SNP</intervention_name>
    <description>Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a de novo kidney transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with a de novo kidney graft and age &gt;18 and &lt; 75&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  panel of antigens reactivity &gt; 40%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gürkan Sengölge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine III, Division of Nephrology</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>September 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2009</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Guerkan SENGOELGE</investigator_full_name>
    <investigator_title>Assoc. Prof. Priv.-Doz. Dr.</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>single nucleotide polymorphism</keyword>
  <keyword>IMPDH</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

